A recent study by Israel's Ministry of Health indicates that ADHD medication consumption has surged by 98% from 2020 to 2025, marking a significant shift in treatment practices. Traditionally dominated by methylphenidate drugs like Ritalin, which held 75% of the market share in 2020, these medications have now fallen to 33%. In contrast, amphetamine-based drugs, including Adderall and Attent, have seen an explosive growth of 675%, now comprising 56% of the ADHD medication market. This dramatic increase has sparked a debate about whether the rise in prescriptions reflects improved diagnosis or a trend towards over-medicalization. Education Minister Yoav Kisch emphasized concerns about potential over-treatment, suggesting that some children may be prescribed medication unnecessarily. Experts advocate for a comprehensive approach to ADHD treatment that includes behavioral interventions alongside medication. The findings prompt urgent questions regarding the adequacy of diagnostic processes and the long-term implications of this shift in medication use.